0001493152-23-017787.txt : 20230516 0001493152-23-017787.hdr.sgml : 20230516 20230516161553 ACCESSION NUMBER: 0001493152-23-017787 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230512 FILED AS OF DATE: 20230516 DATE AS OF CHANGE: 20230516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROUBIN GARY S CENTRAL INDEX KEY: 0001162533 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35731 FILM NUMBER: 23927698 MAIL ADDRESS: STREET 1: 4300 ROCKMORE RD JACKSON CITY: WYOMING STATE: WY ZIP: 83001 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: InspireMD, Inc. CENTRAL INDEX KEY: 0001433607 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 262123838 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 BUSINESS PHONE: (888) 776-6804 MAIL ADDRESS: STREET 1: 4 MENORAT HAMAOR ST. CITY: TEL AVIV STATE: L3 ZIP: 6744832 FORMER COMPANY: FORMER CONFORMED NAME: Saguaro Resources, Inc. DATE OF NAME CHANGE: 20080428 4 1 ownership.xml X0407 4 2023-05-12 0 0001433607 InspireMD, Inc. NSPR 0001162533 ROUBIN GARY S C/O INSPIREMD, INC. 4 MENORAT HAMAOR ST. TEL AVIV L3 6744832 ISRAEL 1 0 0 0 0 Common Stock 2023-05-12 4 P 0 61249 1.6327 A 233545 D Series H Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 30625 1.6327 A 2023-05-15 Common Stock 30625 30625 D Series I Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 30624 1.6327 A 2023-05-15 Common Stock 30624 30624 D Series J Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 30625 1.6327 A 2023-05-15 Common Stock 30625 30625 D Series K Warrants to purchase Common Stock 1.3827 2023-05-12 4 P 0 30624 1.6327 A 2023-05-15 Common Stock 30624 30624 D The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement"). The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327. The aggregate number of warrants reported in this row consists of 30,625 Series H Warrants that were acquired in the Private Placement. The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial. The aggregate number of warrants reported in this row consists of 30,624 Series I Warrants that were acquired in the Private Placement. The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm). The aggregate number of warrants reported in this row consists of 30,625 Series J Warrants that were acquired in the Private Placement. The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm. The aggregate number of warrants reported in this row consists of 30,624 Series K Warrants that were acquired in the Private Placement. The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin. /s/ Craig Shore, Attorney-in-Fact for Gary S. Roubin 2023-05-16